阿尔茨海默病风险基因SORL1是激发性神经元功能的调节者
C Andrew Williams1,2, Shannon E Rose1,2, Vera Stamenkovic3
1Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA.
bioRxiv : the preprint server for biology
|August 6, 2025
概括
在阿尔茨海默氏病 (AD) 模型中,SORL1蛋白质的损失会损害突触功能和可塑性. 这种功能障碍源于改变的蛋白质贩运,而不是粉样β,突出显示了AD治疗的SORL1-复原体通路.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 遗传学 遗传学 是一个
背景情况:
- 突触功能障碍是阿尔茨海默病 (AD) 的早期标志,有助于认知能力下降.
- 内体细胞回收和贩运对于突触蛋白位址至关重要.
- SORL1基因及其蛋白质产物SORLA涉及AD病变发生,并与逆转激素复合体相互作用以调节内体循环.
研究的目的:
- 研究SORL1在突触蛋白组成和神经元功能中的作用,使用人类诱导多能干细胞 (hiPSC) 衍生的神经元.
- 研究SORL1缺乏如何影响突触蛋白相互作用和神经元活动.
主要方法:
- 利用来自SORL1淘汰赛和同源控制线的hiPSC衍生的刺激性皮质神经元.
- 用量的多重共免疫沉 (QMI) 来进行中介质蛋白质相互作用的中介质蛋白质组学分析.
- 通过免疫细胞化学评估突触结构,AMPA受体子单元和使用多电极阵列 (MEAs) 的神经元功能.
主要成果:
- 失去SORL1显著改变了突触蛋白-蛋白相互作用和表达模式.
- 缺少SORL1的神经元表现出由谷氨基基质神经传递驱动的过度活动,主要是由于突触蛋白误导.
- 在缺乏SORL1的神经元中观察到突触可塑性受损.
结论:
- 由SORL1功能障碍驱动的早期内分体循环中的缺陷,有助于阿尔茨海默病的发病.
- SORL1-逆转基因通路代表了阿尔茨海默病治疗开发的一个有希望的目标.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Neural Regulation
40.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.0K
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K


